Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy

Trial Profile

Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 16 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 18 Aug 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2011-0509)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top